Advertisement

Neurological Sciences

, Volume 33, Issue 1, pp 201–208 | Cite as

Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease

  • Massimo Musicco
  • Alessandro Padovani
  • Sandro Sorbi
  • Elio Scarpini
  • Paolo Caffarra
  • Stefano Cappa
  • Francesca Clerici
  • Massimo Tabaton
  • Carlo Caltagirone
  • Vincenzo Bonavita
  • Amalia C. Bruni
  • Giuseppe Bruno
  • Antonio Federico
  • Carlo Ferrarese
  • Camillo Marra
  • Benedetta Nacmias
  • Lucilla Parnetti
  • Carla Pettenati
  • Giuseppe Sorrentino
  • Fabrizio Tagliavini
  • Claudio Mariani
SIN DOCUMENT

Abstract

A panel of Italian neurologists of the Italian Society for the study of Dementias (SINDEM) discussed the recently proposed new lexicon for Alzheimer disease (AD) and the related diagnostic criteria for the different phases of the disease (Preclinical AD, prodromal AD and Alzheimer’s dementia) (Dubois et al. in Lancet Neurol 6:734–746, 2007; in Lancet Neurol 9:1118–1127, 2010). The aim of this discussion was to reach a consensus, among the Italian neurologists involved in the study and care of persons with dementia, in particular in reference to the potential use of the proposed diagnostic criteria in clinical practice. After having critically revised the scientific evidence related to the new lexicon and to the new proposed diagnostic criteria, the panel concluded that the proposed new diagnostic criteria and the new proposed lexicon for AD are conceptually attractive. However, the evidence about the instrumental and laboratory markers for the diagnosis of the preclinical and asymptomatic states of the disease are, until to now, insufficient to support the routine clinical use of these investigations.

Keywords

Alzheimer’s disease Diagnostic criteria Biomarkers Expert opinion 

References

  1. 1.
    Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746PubMedCrossRefGoogle Scholar
  2. 2.
    Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9:1118–1127PubMedCrossRefGoogle Scholar
  3. 3.
    Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC (2006) Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol 5:828–834PubMedCrossRefGoogle Scholar
  4. 4.
    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Co DLB (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRefGoogle Scholar
  5. 5.
    McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, Disease WGoFDaPs (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol 58:1803–1809PubMedCrossRefGoogle Scholar
  6. 6.
    Gainotti G (2010) Origins, controversies and recent developments of the MCI construct. Curr Alzheimer Res 7:271–279PubMedCrossRefGoogle Scholar
  7. 7.
    Viswanathan A, Rocca WA, Tzourio C (2009) Vascular risk factors and dementia: how to move forward? Neurology 72:368–374PubMedCrossRefGoogle Scholar
  8. 8.
    White L (2010) Educational attainment and mid-life stress as risk factors for dementia in late life. Brain 133:2180–2182PubMedCrossRefGoogle Scholar
  9. 9.
    Kivipelto M, Helkala E-L, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137:149–155PubMedGoogle Scholar
  10. 10.
    Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES, Cox NJ, Dunbar-Jacob JM, Granieri EC, Hunt G, McGarry K, Patel D, Potosky AL, Sanders-Bush E, Silberberg D, Trevisan M (2010) National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med 153:176–181PubMedGoogle Scholar
  11. 11.
    Mitchell AJ, Shiri-Feshki M (2009) Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica 119:252–265Google Scholar
  12. 12.
    Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, Dekosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509–1517PubMedCrossRefGoogle Scholar
  13. 13.
    Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446–452PubMedCrossRefGoogle Scholar
  14. 14.
    Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, Initiative AsDN (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132:1355–1365PubMedCrossRefGoogle Scholar
  15. 15.
    Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain 130:2837–2844PubMedCrossRefGoogle Scholar
  16. 16.
    Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64:343–349PubMedCrossRefGoogle Scholar
  17. 17.
    Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66:1469–1475PubMedCrossRefGoogle Scholar
  18. 18.
    Henneman WJP, Vrenken H, Barnes J, Sluimer IC, Verwey NA, Blankenstein MA, Klein M, Fox NC, Scheltens P, Barkhof F, van der Flier WM (2009) Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 73:935–940PubMedCrossRefGoogle Scholar
  19. 19.
    Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69:631–639PubMedCrossRefGoogle Scholar
  20. 20.
    Schott JM, Bartlett JW, Fox NC, Barnes J (2010) Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol 68:825–834Google Scholar
  21. 21.
    Rossor MN, Fox NC, Beck J, Campbell TC, Collinge J (1996) Incomplete penetrance of familial Alzheimer’s disease in a pedigree with a novel presenilin-1 gene mutation. Lancet 347:1560PubMedCrossRefGoogle Scholar
  22. 22.
    Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu C-E, Bird TD (2010) Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 133:1143–1154PubMedCrossRefGoogle Scholar
  23. 23.
    Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, Spina S, Coppola G, Karydas AM, Stewart H, Johnson N, Hsiung G-Y, Kelley B, Kuntz K, Steinbart E, Wood EM, Yu C-E, Josephs K, Sorenson E, Womack KB, Weintraub S, Pickering-Brown SM, Schofield PR, Brooks WS, Van Deerlin VM, Snowden J, Clark CM, Kertesz A, Boylan K, Ghetti B, Neary D, Schellenberg GD, Beach TG, Mesulam M, Mann D, Grafman J, Mackenzie IR, Feldman H, Bird T, Petersen R, Knopman D, Boeve B, Geschwind DH, Miller B, Wszolek Z, Lippa C, Bigio EH, Dickson D, Graff-Radford N, Hutton M (2007) Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C– > T (Arg493X) mutation: an international initiative. Lancet Neurol 6:857–868PubMedCrossRefGoogle Scholar
  24. 24.
    Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, Michel B, Puel M, Volteau M, Touchon J, Verny M, Dubois B (2007) Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 69:1859–1867PubMedCrossRefGoogle Scholar
  25. 25.
    Bäckman L, Jones S, Berger A-K, Laukka EJ, Small BJ (2005) Cognitive impairment in preclinical Alzheimer’s disease: a meta-analysis. Neuropsychology 19:520–531PubMedCrossRefGoogle Scholar
  26. 26.
    Davidson JE, Irizarry MC, Bray BC, Wetten S, Galwey N, Gibson R, Borrie M, Delisle R, Feldman HH, Hsiung G-Y, Fornazzari L, Gauthier S, Guzman D, Loy-English I, Keren R, Kertesz A, George-Hyslop PS, Wherrett J, Monsch AU (2010) An exploration of cognitive subgroups in Alzheimer’s disease. J Int Neuropsychol Soc 16:233–243Google Scholar
  27. 27.
    Carlesimo GA, Perri R, Caltagirone C (2011) Category cued recall following controlled encoding as a neuropsychological tool in the diagnosis of Alzheimer’s disease: a review of the evidence. Neuropsychol Rev 21:54–65Google Scholar
  28. 28.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMedCrossRefGoogle Scholar
  29. 29.
    Selkoe DJ (2000) Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 924:17–25Google Scholar
  30. 30.
    Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC, (ADNI) AsDNI (2009) Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 6:347–361Google Scholar
  31. 31.
    Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1133–1142Google Scholar
  32. 32.
    Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, Schmansky NJ, Greve DN, Salat DH, Buckner RL, Fischl B (2009) Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer’s disease. Brain 132:2048–2057Google Scholar
  33. 33.
    Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT (2009) Age, Alzheimer disease, and brain structure. Neurology 73:1899–1905Google Scholar
  34. 34.
    Davatzikos C, Xu F, An Y, Fan Y, Resnick SM (2009) Longitudinal progression of Alzheimer’s-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain 132:2026–2035Google Scholar
  35. 35.
    Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR, Feldman HH, Bokde ALW, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H, (Adni, Initiative NAAsDN (2010) Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. NBA 1–14Google Scholar
  36. 36.
    Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR, Weiner MW, Jagust WJ, Initiative AsDN (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75:230–238Google Scholar
  37. 37.
    Costafreda SG, Dinov ID, Tu Z, Shi Y, Liu C-Y, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Wahlund L-O, Spenger C, Toga AW, Lovestone S, Simmons A (2011) Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. NeuroImage 56:1–8Google Scholar
  38. 38.
    DeCarli C, Frisoni G, Clark C, Harvey D, Grundman M, Petersen R, Thal L, Jin S, Jack Jr C, Scheltens P (2007) Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 64:108–115Google Scholar
  39. 39.
    Visser PJ, Verhey FRJ, Hofman PAM, Scheltens P, Jolles J (2002) Medial temporal lobe atrophy predicts Alzheimer’s disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatr 491–497Google Scholar
  40. 40.
    Mosconi L, Pupi A, de Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann New York Acad Sci 1147:180–195Google Scholar
  41. 41.
    Chételat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron J-C (2003) Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 60:1374–1377Google Scholar
  42. 42.
    Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46:1625–1632Google Scholar
  43. 43.
    Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, Cappa S, Lenz O, Ludecke S, Marcone A, Mielke R, Ortelli P, Padovani A, Pelati O, Pupi A, Scarpini E, Weisenbach S, Herholz K, Salmon E, Holthoff V, Sorbi S, Fazio F, Perani D (2005) Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 62:1728–1733Google Scholar
  44. 44.
    Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73:754–760Google Scholar
  45. 45.
    Glodzik-Sobanska L, Pirraglia E, Brys M, De Santi S, Mosconi L, Rich KE, Switalski R, Louis LS, Sadowski MJ, Martiniuk F (2009) The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer’s disease. Neurobiol Aging 30:672–681Google Scholar
  46. 46.
    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S-K, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385–393Google Scholar
  47. 47.
    Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM-Y, Trojanowski JQ (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 1–13Google Scholar
  48. 48.
    Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234Google Scholar
  49. 49.
    Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ (2009) Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30:682–690Google Scholar
  50. 50.
    Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L-O, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8:619–627Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Massimo Musicco
    • 1
  • Alessandro Padovani
    • 2
  • Sandro Sorbi
    • 3
  • Elio Scarpini
    • 4
  • Paolo Caffarra
    • 5
  • Stefano Cappa
    • 6
  • Francesca Clerici
    • 7
  • Massimo Tabaton
    • 8
  • Carlo Caltagirone
    • 9
    • 10
  • Vincenzo Bonavita
    • 12
  • Amalia C. Bruni
    • 13
  • Giuseppe Bruno
    • 14
  • Antonio Federico
    • 15
  • Carlo Ferrarese
    • 16
  • Camillo Marra
    • 17
  • Benedetta Nacmias
    • 18
  • Lucilla Parnetti
    • 19
  • Carla Pettenati
    • 20
  • Giuseppe Sorrentino
    • 21
  • Fabrizio Tagliavini
    • 22
  • Claudio Mariani
    • 11
  1. 1.Institute of Biomedical Technologies, National Research Council, Segrate (Mi)Foundation IRCCS “Santa Lucia”RomeItaly
  2. 2.Department of Neurological SciencesUniversity of BresciaBresciaItaly
  3. 3.Department of Neurological SciencesUniversity of FlorenceFlorenceItaly
  4. 4.Department of NeurosciencesUniversity of MilanMilanItaly
  5. 5.Department of Neurosciences and Centre for Cognitive DisordersUniversity of Parma and AUSL of ParmaParmaItaly
  6. 6.Faculty of PsychologyUniversity “Vita e Salute”MilanItaly
  7. 7.Centre for Research and Treatment of Cognitive Dysfunctions, Chair of Neurology “Luigi Sacco” HospitalUniversity of MilanMilanItaly
  8. 8.Department of Internal Medicine and Medical SpecialitiesUniversity of GenovaGenovaItaly
  9. 9.Department of NeurologyUniversity “Tor Vergata”RomeItaly
  10. 10.Foundation IRCCS “Santa Lucia”RomeItaly
  11. 11.Department of Neurology, “L. Sacco” HospitalUniversity of MilanMilanItaly
  12. 12.Department of NeurologyUniversity “Federico II”NaplesItaly
  13. 13.Regional Center of NeurogeneticsLamezia TermeItaly
  14. 14.Department of Neurology and PsychiatryUniversity “La Sapienza”RomeItaly
  15. 15.Department of Neurological, Neurosurgical and Behavioural SciencesUniversity of SienaSienaItaly
  16. 16.Department of Neurosciences and Biomedical TechnologiesUniversity of Milano-BicoccaMilanItaly
  17. 17.Department of NeuroscienceCatholic University of RomeRomeItaly
  18. 18.Department of neurological SciencesUniversity of FlorenceFlorenceItaly
  19. 19.Department of NeurologyUniversity of PerugiaPerugiaItaly
  20. 20.Alzheimer Center“G. Salvini” Hospital Passirana di RhoMilanItaly
  21. 21.Faculty of Motor SciencesUniversity “Parthenope”NaplesItaly
  22. 22.National Neurological Institute IRCCS “C. Besta”MilanItaly

Personalised recommendations